Strontium compound for treatment of sub-dermal soft tissue pain

Abstract

The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.

1 . A method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a said subject in need thereof an effective amount of a physiologically tolerable strontium compound.  
   
   
       2 . A method as claimed in  claim 1 , wherein said strontium compound is administered to the surface of the skin.  
   
   
       3 . A method as claimed in  claim 1 , wherein said soft tissue is muscle.  
   
   
       4 . (canceled)  
   
   
       5 . A pain relieving topical pharmaceutical composition comprising a physiologically tolerable strontium compound, a physiologically tolerable carrier and a physiologically tolerable skin penetration enhancing agent.  
   
   
       6 . A composition as claimed in  claim 5 , wherein said skin penetration enhancing agent is dimethylsulphoxide.  
   
   
       7 . A pain relieving pharmaceutical composition comprising a physiologically tolerable strontium compound and a physiologically tolerable bioadhesive, optionally together with a physiologically tolerable carrier or excipient.  
   
   
       8 . A composition as claimed in  claim 5 , wherein said strontium compound is strontium chloride or strontium nitrate.  
   
   
       9 . An iontophoretic assembly comprising a cathode in electrical contact with a drug reservoir, characterized in that said drug reservoir contains a physiologically tolerable strontium compound.  
   
   
       10 . A salt or complex of strontium and a physiologically tolerable non-salicylate, non-oxicam cyclooxygenase inhibitor.  
   
   
       11 . A pharmaceutical composition comprising a salt or complex of strontium and a physiologically tolerable non-salicylate, non-oxicam cyclooxygenase inhibitor together with a pharmaceutical carrier or excipient.  
   
   
       12 . A salt or complex of strontium and an alpha amino acid.  
   
   
       13 . A pharmaceutical composition comprising a salt or complex of strontium and an alpha amino acid together with a pharmaceutical carrier or excipient.  
   
   
       14 . A salt or complex of strontium and a physiologically tolerable diethylenetriamine- or tetraazacyclododecane-backboned chelating agent.  
   
   
       15 . A pharmaceutical composition comprising a salt or complex of strontium and a physiologically tolerable diethylenetriamine- or tetraazacyclododecane-backboned chelating agent together with a pharmaceutical carrier or excipient.  
   
   
       16 . (canceled)  
   
   
       17 . A method of treatment of a human or other mammalian subject experiencing symptoms of herpetic infection, said method comprising administering to said subject an effective amount of a physiologically tolerable strontium compound.